ANDA 40620, held by Teva Pharmaceuticals USA. Methylprednisolone Acetate.
As of Nov 21, 2026, ANDA 40620 (Methylprednisolone Acetate), held by Teva Pharmaceuticals USA, was first approved by FDA on Oct 27, 2006, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 27, 2006 | Original application | Approved |
| Methylprednisolone Acetate40MG/ML ยท injectable;injection | Methylprednisolone Acetate | Discontinued |
| Methylprednisolone Acetate80MG/ML ยท injectable;injection | Methylprednisolone Acetate | Discontinued |
| Aug 24, 2022 | Supplement 31Labeling ยท Standard review | Approved | None posted |
| Aug 9, 2020 | Supplement 30Labeling ยท Standard review | Approved | None posted |
| Aug 9, 2020 | Supplement 26Labeling ยท Standard review | Approved | None posted |
| Aug 9, 2020 | Supplement 24Labeling ยท Standard review | Approved | None posted |
| Aug 9, 2020 | Supplement 22Labeling ยท Standard review | Approved | None posted |
| Nov 30, 2010 | Supplement 3Labeling | Approved | None posted |
| Oct 27, 2006 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters